Inovio Pharmaceuticals, Inc. (INO)

Market Cap	140.73M
Revenue (ttm)	591,858
Net Income (ttm)	-121.64M
Shares Out	25.96M
EPS (ttm)	-5.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,642
Open	5.35
Previous Close	5.33
Day's Range	5.33 - 5.56
52-Week Range	3.84 - 14.75
Beta	0.82
Analysts	Buy
Price Target	21.17 (+290.59%)
Earnings Date	Nov 7, 2024

About INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 12, 1998
• Employees: 122
• Stock Exchange: NASDAQ
• Ticker Symbol: INO
• Website: https://www.inovio.com

Financial Performance

In 2023, Inovio Pharmaceuticals's revenue was $832,010, a decrease of -91.89% compared to the previous year's $10.26 million. Losses were -$135.12 million, -51.71% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for INO stock is "Buy." The 12-month stock price forecast is $21.17, which is an increase of 290.59% from the latest price.

Price Target

$21.17

(290.59% upside)

Analyst Consensus: Buy